These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 34185898)
1. Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020. Green FG; Park K; Burckart GJ J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S28-S35. PubMed ID: 34185898 [TBL] [Abstract][Full Text] [Related]
2. A Call for Objective Dose Selection to Increase Success in Pediatric Clinical Trials: A Perspective From NICHD and NIMH Program Staff. Giacoia G; Grabb MC; Pawlyk AC; Ren Z; Samedy-Bates L; Taylor-Zapata P J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S9-S12. PubMed ID: 34185908 [No Abstract] [Full Text] [Related]
3. Progress in Drug Development-Pediatric Dose Selection: Workshop Summary. Wang J; van den Anker JN; Burckart GJ J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S13-S21. PubMed ID: 34185909 [TBL] [Abstract][Full Text] [Related]
4. Status Toward the Implementation of Precision Dosing in Children. Barrett JS; Barrett RF; Vinks AA J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S36-S51. PubMed ID: 34185896 [TBL] [Abstract][Full Text] [Related]
5. The European Medicines Agency Experience With Pediatric Dose Selection. Manolis E; Musuamba FT; Karlsson KE J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S22-S27. PubMed ID: 34185894 [TBL] [Abstract][Full Text] [Related]
6. Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children. Vinks AA; Barrett JS J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S52-S59. PubMed ID: 34185897 [TBL] [Abstract][Full Text] [Related]
7. Dosing Recommendations for Pediatric Patients With Renal Impairment. Al-Khouja A; Park K; Anderson DJC; Young C; Wang J; Huang SM; Khurana M; Burckart GJ J Clin Pharmacol; 2020 Dec; 60(12):1551-1560. PubMed ID: 32542790 [TBL] [Abstract][Full Text] [Related]
8. Drug Safety in Labeling for Pediatric Drug Development and Dose Selection in Submissions to the US Food and Drug Administration. Kim C; Park K; McMahon AW; Green FG; Green DJ; Burckart GJ J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S133-S140. PubMed ID: 34185899 [TBL] [Abstract][Full Text] [Related]
9. Neonatal and Pediatric Dose Selection: Quo Vadis? Burckart GJ; van den Anker JN J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S7-S8. PubMed ID: 34185900 [No Abstract] [Full Text] [Related]
10. Real-World Data for Pediatric Pharmacometrics: Can We Upcycle Clinical Data for Research Use? Van Driest SL; Choi L Clin Pharmacol Ther; 2019 Jul; 106(1):84-86. PubMed ID: 30942897 [No Abstract] [Full Text] [Related]
11. A Systematic Assessment of US Food and Drug Administration Dosing Recommendations For Drug Development Programs Amenable to Response-Guided Titration. Wang L; Maxfield K; Guinn D; Madabushi R; Zineh I; Schuck RN Clin Pharmacol Ther; 2021 Jan; 109(1):123-130. PubMed ID: 33022770 [TBL] [Abstract][Full Text] [Related]
12. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678 [TBL] [Abstract][Full Text] [Related]
13. Improving pediatric dosing through pediatric initiatives: what we have learned. Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202 [TBL] [Abstract][Full Text] [Related]
14. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling. Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249 [TBL] [Abstract][Full Text] [Related]
15. Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020. Abulwerdi GA; Ramamoorthy A; Bashaw E; Burckart GJ; Madabushi R; Fletcher EP Clin Transl Sci; 2023 Oct; 16(10):2046-2057. PubMed ID: 37551830 [TBL] [Abstract][Full Text] [Related]
16. Pediatric antihypertensive trial failures: analysis of end points and dose range. Benjamin DK; Smith PB; Jadhav P; Gobburu JV; Murphy MD; Hasselblad V; Baker-Smith C; Califf RM; Li JS Hypertension; 2008 Apr; 51(4):834-40. PubMed ID: 18332283 [TBL] [Abstract][Full Text] [Related]
17. Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development. Mulugeta Y; Barrett JS; Nelson R; Eshete AT; Mushtaq A; Yao L; Glasgow N; Mulberg AE; Gonzalez D; Green D; Florian J; Krudys K; Seo S; Kim I; Chilukuri D; Burckart GJ J Clin Pharmacol; 2016 Nov; 56(11):1326-1334. PubMed ID: 27040726 [TBL] [Abstract][Full Text] [Related]
18. Primary Endpoints in Pediatric Efficacy Trials Submitted to the US FDA. Green DJ; Burnham JM; Schuette P; Liu XI; Maas BM; Yao L; McCune SK; Chen J; van den Anker JN; Burckart GJ J Clin Pharmacol; 2018 Jul; 58(7):885-890. PubMed ID: 29663424 [TBL] [Abstract][Full Text] [Related]
19. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience? Ren Z; Zajicek A Semin Perinatol; 2015 Nov; 39(7):530-1. PubMed ID: 26455383 [TBL] [Abstract][Full Text] [Related]
20. Bridging Adult Experience to Pediatrics in Oncology Drug Development. Leong R; Zhao H; Reaman G; Liu Q; Wang Y; Stewart CF; Burckart G J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S129-S135. PubMed ID: 28921643 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]